Results 51 to 60 of about 41,379 (243)

Messaging to Increase Public Support for Naloxone Distribution Policies in the United States: Results from a Randomized Survey Experiment. [PDF]

PLoS ONE, 2015
Barriers to public support for naloxone distribution include lack of knowledge, concerns about potential unintended consequences, and lack of sympathy for people at risk of overdose.A randomized survey experiment was conducted with a nationally ...
Marcus A Bachhuber, Emma E McGinty, Alene Kennedy-Hendricks, Jeff Niederdeppe, Colleen L Barry   +4 more
doaj   +1 more source

Medicaid Managed Care Plan Alignment With State Substance Use Disorder Treatment Coverage Requirements

The Milbank Quarterly, EarlyView.
Policy Points States contract with Medicaid managed care plans to administer benefits for roughly 70 million Medicaid enrollees, yet little is known about how plan benefit policies for substance use disorder (SUD) treatment medications align with state requirements.
SAGE R. FELTUS, CHRISTINA M. ANDREWS, LAUREN PETERSON, COLLEEN M. GROGAN, AMANDA J. ABRAHAM, OLIVIA M. HINDS, MAUREEN T. STEWART   +6 more
wiley   +1 more source

Toronto's drug policy paradox: Harm reduction sites and drug police occurrences in Toronto neighborhoods (1992–2020)

Criminology, EarlyView.
Abstract Discourse around drug policy presents a stark contrast between policing and harm reduction models, sparking debates on the state's regulatory versus protective role. Canada is an ideal case to study drug policy models due to its global recognition as a leader in harm reduction alongside continued reliance on policing of drugs.
Taylor Domingos
wiley   +1 more source

Factors associated with gaps in naloxone knowledge: evidence from a 2022 great plains survey

Harm Reduction Journal
Background The rising prevalence of fast-acting opioids in the USA suggests the increased need for non-professional first responder administration of naloxone.
Spencer Cooper-Ohm, Patrick Habecker, Ryan Humeniuk, Rick A. Bevins   +3 more
doaj   +1 more source

Use of urinary naloxone levels in a single provider practice: a case study

Addiction Science & Clinical Practice, 2020
Background Urine drug monitoring for medications for opioid use disorder (MOUD) such as buprenorphine can help to support treatment adherence. The practice of introducing unconsumed medication directly into urine (known as “spiking” samples) has been ...
Jill S. Warrington, Kaitlyn Booth, Gregory S. Warrington, Samuel Francis-Fath   +3 more
doaj   +1 more source

Intention to get naloxone among patients prescribed opioids for chronic pain

Harm Reduction Journal, 2022
Background Prescription opioids have been increasingly prescribed for chronic pain while the opioid-related death rates grow. Naloxone, an opioid antagonist, is increasingly recommended in these patients, yet there is limited research that investigates ...
Yinan Huang, Ning Lyu, Shrey Gohil, Shweta Bapat, E. James Essien, J. Douglas Thornton   +5 more
doaj   +1 more source

Trajectories of medication for opioid use disorder and their impact on HIV testing among people who inject drugs in India: A longitudinal assessment of clinic‐based data

Addiction, Volume 120, Issue 4, Page 745-755, April 2025.
Abstract Aims The aim of this study was to identify longitudinal trajectories of medication for opioid use disorder (MOUD) use throughout 1 year following MOUD initiation and to examine the association of trajectory membership with HIV testing among people who inject drugs in India.
Allison M. McFall, Lakshmi Ganapathi, Mihili P. Gunaratne, Aylur K. Srikrishnan, Conjeevaram K. Vasudevan, Santhanam Anand, Sunil S. Solomon, Shruti H. Mehta, Gregory M. Lucas   +8 more
wiley   +1 more source

Healthcare utilization and mortality after overdose prevention site closure: A linked cohort analysis using segmented difference‐in‐differences time series

Addiction, EarlyView.
Abstract Background and aims Evidence regarding the impacts of supervised drug consumption services (SDC) remains mixed, and few evaluations have used individual‐level, linkable health data to examine service withdrawal. In September 2024, the Red Deer overdose prevention site (OPS) in Alberta, Canada, was scheduled for closure, with operations ceasing
Nathaniel Day, Kym Kaufmann, Daniel John Alexander Devoe, Vanja Grubac, Alessia DiMarzo, Haisa Osmanli, Vanessa Norton, Shelly Vik, Nickie Mathew, Robert Lawrence Tanguay, Anees Bahji   +10 more
wiley   +1 more source

Use of low-threshold naloxone boxes for opioid overdose prevention in a Midwestern US State: a public health program evaluation

Harm Reduction Journal
Introduction Despite reductions in overdose deaths reported nationally in 2025, overdose remains a leading cause of death in Michigan and the broader United States.
Pamela S. Lynch, Lou Gamalski, Virginia Roys, Autumn Albers, Katie Burk, Sara Durán, Shelley N. Facente   +6 more
doaj   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source